Chair Cassidy Applauds FDA Approval of New Lifesaving Treatment for Americans with Liver Disease

WASHINGTON - Today, U.S. Senator Bill Cassidy, M.D. (R-LA), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, applauded the U.S. Food and Drug Administration's approval of the first GLP-1 drug to treat patients with metabolic-associated steatohepatitis (MASH), a serious liver disease that affects approximately 14.9 million Americans.

"As a liver doctor who practiced for decades, I'm very aware of the significance of this development. It will save a tremendous amount of money and disease burden, including transplantation and death," said Dr. Cassidy. "Medical research saves money in the long-term, and continued federal support for biomedical innovation is essential to discovering new lifesaving treatments."

At a HELP hearing last year on weight-loss drugs, Cassidy underscored the need to incentivize lifesaving innovation while ensuring Americans can afford new treatments.

###

For all news and updates from HELP Republicans, visit our websiteor Twitterat @GOPHELP.